How are small molecule drugs developed?
Small molecule drugs, typically organic compounds with low molecular weight that easily penetrate cells, are developed through interdisciplinary methods such as rational drug design, natural source isolation, phenotypic screening, and target-based drug discovery, and are widely used in medicinal applications including novel cancer therapies and RNA-targeting biochemical regulation.
Small molecule drugs are organic compounds that affect a variety of molecular pathways, primarily by targeting key proteins. Such compounds have a low molecular weight, allowing them to easily penetrate cells. Small drugs are developed from leads that derive from rational drug design or are isolated from nature.
The discovery of small molecule drugs is a complex process that requires interdisciplinary expertise. Small molecules can be obtained through:
-
Rational drug design: The development of medications based on the study of the structure and function of target molecules. This is a methodological approach rather than a brute force approach conducted through a high volume of tests and experiments.
-
Isolation from natural sources: A multidisciplinary approach using natural sources as pharmacological leads against many different diseases.
-
Phenotypic screening: Using cell-based assays. These assays measure a phenotype in physiological systems, which includes all preclinical assay formats using physiological systems.
-
Target-based drug discovery: Involves target identification and validation, assay development, hit identification, hit to lead, lead optimization, and candidate selection and development.
What are small molecules used for?
Small molecules have enormous biological and medicinal applications, most importantly being their potential as novel cancer therapies. Small molecules are one category of drugs that are defined by their production by chemical synthesis. Some examples include:
- Aspirin
- Felbamate
- Varenicline
Small molecules are typically between 0.1 and 1 kDa in size and have relatively simple structures that do not trigger an immune response. One key area for their application includes the identification and development of molecular entities capable of targeting RNA, offering almost endless biochemical applications such as:
- Regulation of polymerase reactions
- Viral infectivity
- Gene expression and storage
Related
Data Management, Collaboration, and Workflow Optimisation: The Three Keys to Small Molecule Discovery Success
The article emphasizes that despite biologics' prominence, small molecule drug discovery is experiencing a renaissance driven by advances in screening, target exploration, and AI, but overcoming challenges like rising costs, data management, fragmented workflows, and CRO reliance requires success in three key areas: next-generation data management, enhanced cross-disciplinary research collaboration, and workflow optimization.
Principles and Processes of Early Drug Discovery
The early drug discovery process involves target identification and validation, hit discovery through confirming active compounds, assay development for testing effects, and employs various screening strategies such as high-throughput, virtual, phenotypic, and target-based screening to identify promising drug candidates.
Webinar: How to profit from recent innovations in small molecule drug discovery
The webinar, led by Dotmatics’ Director of Product Marketing Haydn Boehm on September 29 at 14:00 BST, will explore the resurgence and innovation in small molecule drug discovery, addressing current research landscapes, challenges, and strategies for optimizing data integration and workflows to accelerate drug candidate identification and reduce costs.
Webinar: Three Key Considerations When Implementing AI in Drug Discovery
The webinar, led by Haydn Boehm, focuses on three key considerations—reasonable expectations, clean data, and collaboration—for successfully implementing AI in small molecule drug discovery amidst the current hype and ongoing preclinical development of AI-native candidates.
FAQ center
The FAQ center explains that lab automation uses data science to create intelligent systems reducing human input, digital labs fully digitize operations for efficiency, future labs will heavily rely on robotics and integrated data management, lab compliance ensures safe and effective lab practices, data integrity ensures reliable data quality, scientific data management systems (SDMS) facilitate safe and accessible scientific data handling, and open data differs from FAIR data in accessibility and usability requirements.
Webinar: The New Era of Small Molecule Drug Discovery
The webinar on August 18 at 4pm BST/11am EDT, featuring Haydn Boehm—an experienced organic chemist and life science industry leader—will address the challenges in small molecule drug discovery and demonstrate strategies to reduce risks, costs, and time to accelerate therapeutic breakthroughs.